

***Klebsiella pneumoniae*, Strain MRSN 761403**

Catalog No. NR-55603

This reagent is the tangible property of the U.S. Government.

Product Description:

Klebsiella pneumoniae (*K. pneumoniae*), strain MRSN 761403 was isolated in 2020 from a human blood sample in North America as part of a global surveillance program. NR-55603 was deposited as an extensively drug-resistant strain, sensitive to ceftazidime/avibactam, gentamicin and tigecycline, intermediately resistant to tetracycline and resistant to amikacin, ampicillin/sulbactam, aztreonam, cefepime, ceftazidime, ceftolozane/tazobactam, ceftriaxone, ciprofloxacin, ertapenem, imipenem, levofloxacin, meropenem, piperacillin/tazobactam, tobramycin and trimethoprim/sulfamethoxazole. NR-55603 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. The material from the initial growth was passaged once in Tryptic Soy broth for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed on Tryptic Soy agar under propagation conditions unless otherwise noted.

Lot: 70051644

Manufacturing Date: 06APR2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth, mucoid and cream
Motility (wet mount)	Report results	Non-motile
VITEK® 2 (GN card)	<i>K. pneumoniae</i> (≥ 89%)	<i>K. pneumoniae</i> (99%)
Antibiotic Susceptibility Profile^{1,2}		
Amikacin	Resistant	Resistant (≥ 64 µg/mL)
Ampicillin/sulbactam	Resistant	Resistant (≥ 32 µg/mL)
Aztreonam	Resistant	Resistant (≥ 64 µg/mL)
Cefepime	Resistant	Resistant (16 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime/avibactam	Sensitive	Sensitive (1 to 1.5 µg/mL)
Ceftolozane/tazobactam	Resistant	Resistant (16 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 32 µg/mL)
Ertapenem	Resistant	Resistant (≥ 8 µg/mL)
Gentamicin	Sensitive	Sensitive (≤ 1 µg/mL)
Imipenem	Resistant	Resistant (≥ 32 µg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Piperacillin/tazobactam	Resistant	Resistant (≥ 128 µg/mL)
Tetracycline	Intermediate	Sensitive (3 to 4 µg/mL) ³
Tigecycline	Sensitive	Resistant (1.5 to 2 µg/mL) ^{4,5}
Tobramycin	Resistant	Resistant (≥ 16 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1460 base pairs)	≥ 99% sequence identity to <i>K. pneumoniae</i> , strain MRSN 761403 (GenBank: JAGYBI010000093.1)	99.4% sequence identity to <i>K. pneumoniae</i> , strain MRSN 761403 (GenBank: JAGYBI010000093.1) ⁶

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

²Antibiotic susceptibility was tested using a combination of bioMérieux VITEK[®]2 GN74 and ETEST[®].

³*K. pneumoniae*, strain MRSN 761403 was deposited as intermediately resistant to tetracycline, but showed a MIC of 3 to 4 µg per mL (interpreted as sensitive) for this antibiotic during QC testing. Testing was performed in duplicate.

⁴MIC Interpretation Guideline: EUCAST Version 8.0 (2018)

⁵The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

⁶Also consistent with other *Klebsiella* species

/Sonia Bjorum Brower/

Sonia Bjorum Brower

18 JUL 2022

Lead Technical Writer or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

